BioCentury | Apr 27, 2018
Clinical News

ADC Therapeutics discontinues HER2 program

...ADC Therapeutics S.A. (Épalinges, Switzerland) said it discontinued ADCT-502 after Phase I data of the antibody-drug...
...with HER2-expressing advanced solid tumors did not show "sufficient patient benefit to justify further development." ADCT-502...
...The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) markets Herceptin trastuzumab to treat HER2-positive cancers. ADCT-502...
BioCentury | Apr 25, 2018
Clinical News

ADC Therapeutics discontinues HER2 program

...ADC Therapeutics S.A. (Épalinges, Switzerland) said it discontinued ADCT-502 after Phase I data of the antibody-drug...
...with HER2-expressing advanced solid tumors did not show "sufficient patient benefit to justify further development." ADCT-502...
...The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) markets Herceptin trastuzumab to treat HER2-positive cancers. ADCT-502...
BioCentury | Oct 27, 2017
Financial News

ADC raises $200M private placement

...ADCT-402, the company has two other programs in the clinic: ADCT-502 and MEDI3726 (formerly ADCT-401). ADCT-502...
...programs, including MEDI3726 (see BioCentury, Oct. 21 ). ADC Therapeutics S.A. , Épalinges, Switzerland Jaime De Leon ADCT-301 ADCT-402 ADCT-502 MEDI3726 AstraZeneca...
BioCentury | Oct 23, 2017
Financial News

ADC Therapeutics raises $200M

...ADCT-402, the company has two other programs in the clinic: ADCT-502 and MEDI3726 (formerly ADCT-401). ADCT-502...
...unit to co-develop two programs, including MEDI3726 (see BioCentury Extra, Oct. 15, 2013) . Jaime De Leon ADCT-301 ADCT-402 ADCT-502 HuMax-TAC-ADC MEDI3726 AstraZeneca...
Items per page:
1 - 4 of 4